Single High-dose of Liposomal Amphotericin B in HIV/AIDS-related Disseminated Histoplasmosis: a Randomized Trial.

Alessandro C Pasqualotto, Daiane Dalla Lana, Cassia S M Godoy,Terezinha do Menino Jesus Silva Leitão, Monica B Bay,Lisandra Serra Damasceno,Renata B A Soares, Roger Kist,Larissa R Silva, Denusa Wiltgen, Marineide Melo,Taiguara F Guimarães, Marilia R Guimarães,Hareton T Vechi,Jacó R L de Mesquita,Gloria Regina de G Monteiro,Antoine Adenis,Nathan C Bahr,Andrej Spec,David R Boulware,Dennis Israelski,Tom Chiller,Diego R Falci

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America（2023）

引用 0|浏览8

暂无评分

摘要

One day induction therapy with 10 mg/kg of L-AmB in AIDS-related histoplasmosis was safe. Although clinical response may be non-inferior to standard L-AmB therapy, a confirmatory phase III clinical trial is needed. A single induction dose would markedly reduce drug-acquisition costs (>4-fold) and markedly shorten and simplify treatment, which are key points in terms of increased access.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要